- Home
- ALKS
ALKS
Alkermes plc
as 04-18-2025 1:30pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 4.5B | IPO Year: | 1991 |
| Target Price: | $38.55 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.17 | EPS Growth: | 3.47 |
| 52 Week Low/High: | $22.90 - $36.45 | Next Earning Date: | 05-01-2025 |
| Revenue: | $1,557,632,000 | Revenue Growth: | -6.36% |
| Revenue Growth (this year): | -9.03% | Revenue Growth (next year): | 4.38% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 26 '25 | Sell | $34.00 | 1,938 | $65,892.00 | 7,717 | |
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 22 '25 | Sell | $35.26 | 3,743 | $131,978.18 | 7,717 | |
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 18 '25 | Sell | $35.69 | 1,327 | $47,360.63 | 7,717 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Feb 12 '25 | Sell | $34.00 | 349,340 | $11,848,975.19 | 166,708 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Jan 30 '25 | Sell | $32.05 | 100,918 | $3,234,381.53 | 166,708 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Alkermes to Report First Quarter Financial Results on May 1, 2025
MT Newswires
16 days ago
RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating
PR Newswire
17 days ago
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Clinical Trials Arena
17 days ago
Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
Zacks
17 days ago
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
PR Newswire
18 days ago
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
MT Newswires
23 days ago
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating
PR Newswire
23 days ago
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.